Boutique CRO Celentyx operates as a boutique CRO with bespoke drug discovery services focused on human immunology, presenting opportunities to position as a high-touch partner for early-stage programs needing specialized assays and translational insights.

Human Immunology Access With access to human primary cells, patient samples, and established hospital partnerships, there is potential to upsell expanded translational services, biomarker discovery, and mechanism-of-action studies for immunology-focused projects.

Established Platforms A broad suite of platforms (flow cytometry, CyTOF, high-content imaging, multiplex assays, proteomics, and molecular biology) enables end-to-end target discovery and screening, offering cross-sell opportunities to pharmaceutical teams needing integrated analytics.

UK translational Links Proximity to Oxford and Birmingham translational medicine ecosystems can be leveraged to secure joint projects, access to clinical records, and collaboration with academic partners to enhance study design and data credibility.

Early-stage Revenue With current revenue under one million, Celentyx represents an opportunity for early engagement with startups and mid-stage biotech firms seeking cost-efficient, high-value immunology-focused CRO support and scalable assay services.